SEC Form 4 · accession 0001179022-16-000132
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilbert S Omenn
Director
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.89 | Dec 15, 2016 | A | 41,500 | A | — | Dec 15, 2026 | Common stock | 41,500 | 41,500 | D |
Explanation of responses
- F1The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting.